Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

ApTOLL: An innovative neuroprotectant to reduce brain damage in Acute Ischemic Stroke (AIS)

Obiettivo

Stroke is a devastating medical condition affecting 15 million people worldwide yearly, being Ischemic Stroke the most frequent (87%). Indeed, the global cost of stroke is >847b (60b in EU) due to the huge socioeconomic burden of disabilities. Reperfusion treatment improves outcomes, but only 20% of patients are currently eligible for treatment due to the narrow therapeutic window after stroke symptom onset and stringent selection criteria for eligibility. Novel therapies - small molecules or biologics - targeting neuroprotection have not achieved enough efficacy to get approved.
aptaTargets has successfully developed ApTOLL, an immune modulator and neuroprotectant with a novel approach TO REDUCE BRAIN DAMAGE in AIS patients. aptaTargets ApTOLL drug has a novel approach targeting TLR4 to reduce brain damage in acute ischemic stroke (AIS) patients (47% reduction of FIV), reduce mortality from 18% to 4% and improve functional outcomes. Due to the innovative MODE OF ACTION AND NATURE of the molecule (an aptamer), ApTOLL represents a novel and disruptive approach to treating stroke in the first hours after the onset (acute phase), substantially reducing brain damage and improving Quality of Life (QoL) in short and long time.
ApTOLL is targeting the Multi-Billion Market of the global Stroke Management Market, valued at 31.7Bn in 2020 and expected to reach 67.7Bn in 2030 (7.8% CAGR). As a first indication within the scope of this EIC Accelerator proposal, ApTOLL will target AIS patients (87%) who received EVT therapy, expecting to be potentially used as neuroprotectant in all stroke patients, based on preclinical and clinical results.
The EIC project aims to conduct the Ph2b trial of ApTOLL and demonstrate its efficacy before entering Ph3. It will boost our chances of licencing the product to a pharma company, increasing the value of the agreement.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) HORIZON-EIC-2023-ACCELERATOR-01

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

APTATARGETS SL
Contributo netto dell'UE
€ 2 498 816,00
Indirizzo
AVDA CARDENAL HERRERA ORIA 298 - 1 PLANTA DESPACHO 4
28035 MADRID
Spagna
PMI
Sì
Regione
Comunidad de Madrid Comunidad de Madrid Madrid
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Collegamenti
Costo totale
€ 3 569 737,25